Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Hongjie Xia; Jing Zou; Chaitanya Kurhade; Hui Cai; Qi Yang; Mark Cutler; David Cooper; Alexander Muik; Kathrin U. Jansen; Xuping Xie; Kena A. Swanson; Pei Yong Shi

doi:10.1016/j.chom.2022.02.015

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei Yong Shi

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.

Original language	English (US)
Pages (from-to)	485-488.e3
Journal	Cell Host and Microbe
Volume	30
Issue number	4
DOIs	https://doi.org/10.1016/j.chom.2022.02.015
State	Published - Apr 13 2022

Keywords

BNT162b2 vaccine
Pfizer vacine
SARS-CoV-2
neutralization
neutralization durability
variants

ASJC Scopus subject areas

Parasitology
Microbiology
Virology

Access to Document

10.1016/j.chom.2022.02.015

Cite this

@article{010afe397cf34ed59cba6833171171ef,

title = "Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2",

abstract = "Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.",

keywords = "BNT162b2 vaccine, Pfizer vacine, SARS-CoV-2, neutralization, neutralization durability, variants",

author = "Hongjie Xia and Jing Zou and Chaitanya Kurhade and Hui Cai and Qi Yang and Mark Cutler and David Cooper and Alexander Muik and Jansen, {Kathrin U.} and Xuping Xie and Swanson, {Kena A.} and Shi, {Pei Yong}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = apr,

day = "13",

doi = "10.1016/j.chom.2022.02.015",

language = "English (US)",

volume = "30",

pages = "485--488.e3",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

AU - Xia, Hongjie

AU - Zou, Jing

AU - Kurhade, Chaitanya

AU - Cai, Hui

AU - Yang, Qi

AU - Cutler, Mark

AU - Cooper, David

AU - Muik, Alexander

AU - Jansen, Kathrin U.

AU - Xie, Xuping

AU - Swanson, Kena A.

AU - Shi, Pei Yong

PY - 2022/4/13

Y1 - 2022/4/13

N2 - Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.

AB - Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.

KW - BNT162b2 vaccine

KW - Pfizer vacine

KW - SARS-CoV-2

KW - neutralization

KW - neutralization durability

KW - variants

UR - http://www.scopus.com/inward/record.url?scp=85125655408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125655408&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2022.02.015

DO - 10.1016/j.chom.2022.02.015

M3 - Article

C2 - 35245438

AN - SCOPUS:85125655408

SN - 1931-3128

VL - 30

SP - 485-488.e3

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 4

ER -

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this